The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESC 2026 | Managing patients flagged as high risk for ATTR-CM: insights into the multidisciplinary approach
Ilia Davarashvili, MD, Leumit Health Services and Leumit Start, Tel Aviv, Israel, comments on the multidisciplinary approach once an AI algorithm flags someone as high risk of cardiac transthyretin amyloidosis (ATTR-CM). Dr Davarashvili highlights that community cardiologists play a crucial role in the initial stages of diagnosis, and once a diagnosis is confirmed, patients can be transferred to specialized teams for further management. This interview took place during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
